Stocks Taking Toll on Profitability Valuation: Colgate-Palmolive (NYSE:CL), The WhiteWave Foods (NYSE:WWAV)

Colgate-Palmolive Company (NYSE:CL) kept active in profitability ratio analysis, on current situation shares price raised 0.12% to $64.61. The total volume of 267310 shares held in the session, while on average its shares change hands 3778.87 shares.

Efficiency Evaluation in Focus

Entering into profitability analysis, the co has noticeable returns on equity ratio of -950.70%, which discloses how corporation’s management efficiently generates profit from shareholders invested money. The returns on investment very popular metric among passive investors, it stands at 42.70%, when it lies in positive figure than security is feasible for investment or goes for higher ROI stocks. To see the other side of picture, profit margin of CL stands at positive 16.10%; that indicates a firm actually every dollar of sales keeps in earnings. The 19.60% returns on assets presents notable condition of firm. Mostly ROA known as a comparative measure, it is best to compare it against a firm’s previous ROA numbers or the ROA of a same firm.

It has forward price to earnings ratio of 20.11, and price to earnings ratio calculated as 23.75. The price to earnings growth ration calculated as 2.73. CL free cash flow concluded as 55.15.

To stick with focus on profitability valuation, The WhiteWave Foods Company (NYSE:WWAV) also listed in significant eye catching mover, WWAV attains returns on investment ratio of 7.30%, which suggests it’s viable on security that has lesser ROI.

To strengthen this concept we can use profit margin, which is standing at positive 4.80%, and it is providing insight view about a variety of aspects of a firm�s financial performance. The operating profit margin and gross profit margin can be giving more focus view that is 9.30% and 34.60% respectively. Turns back to returns ratios, the co’s returns on assets calculated as 7.30%; that gives an idea as to how efficient management is at using its assets to generate earnings. Finally yet importantly, returns on equity stands at 15.10%.

EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 18.70%, and looking further price to next year’s EPS is 15.85%. While take a short look on price to sales ratio, that was 2.34 and price to earning ration of 49.71 attracting passive investors.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *